The global allogenic cell therapy market is expected to reach USD 2.74 billion by 2023 and is anticipated to grow at a CAGR of 14.5% during the forecast period 2023-2035


Allogeneic cell therapies signify prepared treatments sourced from donor tissues like cord blood or bone marrow. These are processed in laboratories, ready for immediate use or storage, eliminating the need for personalized manufacturing per patient. Their advantages lie in consistent quality ensured through rigorous processing controls, cost reduction from centralized manufacturing, and the flexibility to use the same or different donor for subsequent treatments. Additionally, advancements like CRISPR/Cas9 in gene editing have expanded their potential by enabling precise genetic modifications in donor cells, enhancing therapeutic properties, and reducing immune rejection risks.

Recent years have seen global regulatory approval for numerous allogeneic cell therapies across various conditions, including hematological malignancies (e.g., multiple myeloma, leukemia), post-transplant lymphoproliferative disorders (PTLD), neurological and musculoskeletal disorders, autoimmune, and inflammatory conditions. Notably, in December 2022, the European Commission endorsed Ebvallo, an allogeneic T-cell therapy by Atara Biotherapeutics, for treating Epstein-Barr virus positive post-transplant lymphoproliferative disease. Additionally, the FDA approved Osteocel? Plus, an allogeneic mesenchymal stem cell therapy developed by NuVasive, for treating degenerative disc disease. The collaborative efforts of industry and non-industry stakeholders, coupled with rising chronic disease prevalence and challenges in producing autologous cell therapies, are expected to drive substantial growth in the global allogeneic cell therapies market in the forecast period.

Report Coverage
? The report conducts an analysis of the allogenic cell therapy market, focusing on cell therapy types, cell sources, target indications, therapeutic areas, and key geographical regions.
? It evaluates market growth factors such as drivers, restraints, opportunities, and challenges, influencing the industry landscape.
? The report examines potential advantages and hurdles within the market, offering insights into the competitive environment among leading market players.
? Revenue forecasts for market segments are provided concerning four major regions.
? A concise summary outlines the current status and expected evolution of the allogeneic cell therapy market in the mid to long term, drawing from comprehensive research insights.
? An inclusive introduction details allogeneic cell therapy, covering the manufacturing process, primary advantages, challenges, and recent advancements in this specialized market segment.
? A thorough evaluation considers various parameters like establishment year, company size in terms of workforce, headquarters location, development phase (preclinical, clinical, marketed), administration routes, cell therapy types, cell sources, dosing frequency, therapy types, target patient segments, indications, and therapeutic areas.
? Analysis of collaborations among stakeholders since 2019 encompasses research & development agreements, licensing agreements, product development, commercialization agreements, manufacturing/supply agreements, clinical trial agreements, mergers, acquisitions, and other relevant agreements.
? A detailed examination of investments in companies engaged in allogeneic cell therapies, including venture capital financing, IPOs, subsequent offerings, grants, and debt financing. Emphasis is on funding instances between 2019 and 2023, highlighting increased interest from venture capital and strategic investors.
? Scrutiny of completed and ongoing clinical trials related to allogeneic cell therapies, analyzing parameters such as registration year, trial status, phase, design, sponsor types, geographic distribution, and identification of the most active industry and non-industry participants.
? An insightful exploration identifies Key Opinion Leaders (KOLs) involved in allogeneic cell therapy trials, considering KOL types, qualifications, organizational affiliations, geographic locations, and target disease indications. Prominent KOLs are highlighted based on proprietary and third-party scoring criteria.

Key Market Companies
? AbbVie
? Academisch Medisch Centrum
? Acepodia
? Adaptimmune Therapeutics
? Adicet Bio
? Bristol Myers Squibb
? Duke University